Japanese pharmaceutical company Takeda has received approval from the Russian Government Commission for Control over Foreign Investments to sign an agreement with Binergiya JSC. Under the deal, Takeda plans to transfer rights to commercialize part of its retail drug portfolio — which is considered non-core for the company — as well as its production site in Yaroslavl, including real estate, infrastructure, and equipment.
According to Maksim Stetsyuk, CEO of Binergiya Management Company, the agreement is currently being formalized, and it is too early to comment on the details.
Takeda stated that as part of the transaction, Binergiya may obtain the rights to commercialize certain retail products from Takeda’s portfolio across the EAEU countries — Russia, Kazakhstan, Armenia, Kyrgyzstan, and Belarus. Takeda representatives told Vademecum that the deal includes Actovegin (a deproteinized calf blood derivative), Dexilant (dexlansoprazole), Controloc (pantoprazole), and Mezavant (mesalazine). Actovegin is manufactured at the Yaroslavl plant, while the others are imported into Russia.
As part of the transfer, Binergiya will also acquire ownership of the Yaroslavl manufacturing site and assume the plant’s existing contractual obligations. The asset package includes real estate, infrastructure, and equipment. “Once the transaction is complete, the plant’s main activity will shift to contract manufacturing, which is not a core business area for Takeda,” company representatives explained.
According to the agreement, employees of the facility will be offered employment at Binergiya under equivalent conditions. The financial terms of the deal have not been disclosed.
Takeda emphasized that the sale will not affect its operations in Russia: the company will continue functioning as usual and maintain uninterrupted drug supplies. “This transfer is a logical step in Takeda’s strategy to focus on innovative therapies in its core areas — oncology, rare diseases, neurology, gastroenterology, inflammatory diseases, plasma-derived therapies, and vaccines,” the company said in its statement.
Takeda is among the top ten suppliers in Russia’s reimbursed medicines segment. According to analytics firm DSM Group, the company held a 4% share of the government procurement segment in 2024, totaling 12.6 billion rubles in purchases — 10 billion of which came from federal reimbursement programs (14 VZN, ONLS, RLO). Takeda’s most financially successful product in Russia is Elaprase (idursulfase), used to treat hereditary enzyme deficiencies; in 2024, government buyers purchased 3.7 billion rubles’ worth of the drug. Overall, Takeda’s sales in the Russian market are estimated at 33.4 billion rubles.
In 2023, Kommersant reported, citing two sources in the pharmaceutical market, that Takeda was considering selling its Yaroslavl facility. The plant has a production capacity of 90 million ampoules and over 3 billion tablets per year. Over the past decade, Takeda’s investment in the facility totaled €117.43 million. Some of its output is supplied to other EAEU countries. In 2021, Takeda Russia signed an agreement with the Yaroslavl regional government at the St. Petersburg International Economic Forum to invest 2.3 billion rubles by December 2027 in localizing production.
According to SPARK-Interfax, Binergiya JSC was established in 2007 in Balašikha. Its management company is Binergiya Management LLC, and the ultimate beneficiary is Binergiya Group JSC. The company’s website states that it has registered and launched over 100 products, some of which are included in Russia’s list of vital and essential drugs (VED). Its current portfolio includes around 64 positions.
In June 2025, Favorit Trade JSC, another company within the Binergiya Group, signed an agreement with the Kaluga Region government at the St. Petersburg International Economic Forum to build a pharmaceutical plant worth over 1.4 billion rubles. The facility is expected to begin operations in 2026.
Source: Vademecum, September 30, 2025.
